AI Biotech Startup Cradle Raises $24M in Series A Funding

The Dutch company, which uses AI to design proteins more efficiently, plans to use the funding to expand its team and invest in product development.

Cradle, an AI biotech startup, has raised $24 million in a Series A funding round led by Index Ventures, with participation from Kindred Capital and angel investors.
The Dutch startup uses generative AI to design proteins more efficiently, a technology that could significantly accelerate R&D time and reduce costs in the biotech industry.
Cradle's technology has attracted partnerships with major biotech firms including Johnson & Johnson, Novozymes, and Twist Bioscience.
The startup's AI platform has been trained on billions of protein sequences and proprietary data generated in its own wet lab, enabling it to predict alterations to a protein's genetic code that would make it more functional and stable.
With the new funding, Cradle plans to expand its team, invest in product development and sales, and build additional laboratory and engineering facilities in Amsterdam.